68347-91-1

Basic information

• Product Name: (6-PHENYLIMIDAZO[2,1-B][1,3]THIAZOL-3-YL)ACETIC ACID
• Synonyms: 2-(6-phenylimidazo[2,1-b]thiazol-3-yl)acetic acid
• CAS NO: 68347-91-1
• Molecular Formula: C₁₃H₁₀N₂O₂S
• Molecular Weight: 258.3
• Mol File: 68347-91-1.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.42g/cm³
• Refractive Index: 1.718
• CAS DataBase Reference: (6-PHENYLIMIDAZO[2,1-B][1,3]THIAZOL-3-YL)ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (6-PHENYLIMIDAZO[2,1-B][1,3]THIAZOL-3-YL)ACETIC ACID(68347-91-1)
• EPA Substance Registry System: (6-PHENYLIMIDAZO[2,1-B][1,3]THIAZOL-3-YL)ACETIC ACID(68347-91-1)

Safety Data

• Hazardous Substances Data: 68347-91-1(Hazardous Substances Data)

Usage

Description

(6-PHENYLIMIDAZO[2,1-B][1,3]THIAZOL-3-YL)ACETIC ACID is a heterocyclic chemical compound with the molecular formula C13H10N2O2S. It features a thiazole ring with a phenyl substituent, which may contribute to its potential applications in medicinal chemistry. However, further research and studies are required to fully explore its uses and effects.

Uses

Used in Medicinal Chemistry:
(6-PHENYLIMIDAZO[2,1-B][1,3]THIAZOL-3-YL)ACETIC ACID is used as a chemical compound for potential applications in medicinal chemistry due to its unique structure and properties. Its heterocyclic nature and the presence of a thiazole ring with a phenyl substituent may offer various opportunities for drug development and therapeutic interventions. Further research is necessary to understand its full potential and effects in this field.

InChI:InChI=1/C13H10N2O2S/c16-12(17)6-10-8-18-13-14-11(7-15(10)13)9-4-2-1-3-5-9/h1-5,7-8H,6H2,(H,16,17)

Upstream product

• 57626-46-7 3-ethoxycarbonylmethyl-6-phenylimidazo<2,1-b>thiazole 
• 70-11-1 α-bromoacetophenone 
• 121953-08-0 4-ethoxycarbonylmethyl-2-imino-3-phenacyl-2,3-dihydrothiazole 

Downstream Products

• 147248-77-9 (6-Phenyl-imidazo[2,1-b]thiazol-3-yl)-acetyl chloride 
• 147248-78-0 6-phenylimidazo<2,1-b>thiazole-3-(N,N-dimethyl)acetamide 
• 147248-80-4 5-formyl-6-phenylimidazo<2,1-b>thiazole-3-(N,N-dimethyl)acetamide 
• 147248-79-1 6-phenylimidazo<2,1-b>thiazole-3-(N,N-diethyl)acetamide 
• 147248-81-5 5-formyl-6-phenylimidazo<2,1-b>thiazole-3-(N,N-diethyl)acetamide 
• 147248-88-2 β-<3-(N,N-dimethylcarbamoylmethyl)-6-phenylimidazo<2,1-b>thiazol-5-yl>acrylic acid 
• 147248-83-7 5-hydroxyiminomethyl-6-phenylimidazo<2,1-b>thiazole-3-(N,N-diethyl)acetamide 
• 147248-89-3 β-<3-(N,N-diethylcarbamoylmethyl)-6-phenylimidazo<2,1-b>thiazol-5-yl>acrylic acid 
• 147248-99-5 6-phenyl-5-thiosemicarbazonomethylimidazo<2,1-b>thiazole-3-(N,N-dimethyl)acetamide 
• 147249-00-1 6-phenyl-5-thiosemicarbazonomethylimidazo<2,1-b>thiazole-3-(N,N-diethyl)acetamide 

Relevant articles and documents

Synthesis and cytotoxic activity of some novel N-pyridinyl-2-(6- phenylimidazo[2,1-b]thiazol-3-yl)acetamide derivatives

A series of novel compounds bearing imidazo[2,1-b]thiazole scaffolds were designed and synthesized based on the optimization of the virtual screening hit compound N-(6-morpholinopyridin-3-yl)-2-(6-phenylimidazo[2,1-b]thiazol-3-yl) acetamide (5a), and tested for their cytotoxicity against human cancer cell lines, including HepG2 and MDA-MB-231. The results indicated that the compound 2-(6-(4-chlorophenyl)imidazo [2,1-b]thiazol-3-yl)-N-(6-(4-(4-methoxybenzyl) piperazin-1-yl)pyridin-3-yl)acetamide (5l), with slightly higher inhibition on VEGFR2 than 5a (5.72% and 3.76% inhibitory rate at 20 μM, respectively), was a potential inhibitor against MDA-MB-231 (IC50 = 1.4 μM) compared with sorafenib (IC50 = 5.2 μM), and showed more selectivity against MDA-MB-231 than HepG2 cell line (IC50 = 22.6 μM).